Global Anti-tumor Drug Market 2023 by Company, Regions, Type and Application, Forecast to 2029

Description

Anti-tumor drugs are for the treatment of cancer diseases. In recent years, the development of molecular oncology and molecular pharmacology has gradually clarified the nature of the tumor. The invention and application of advanced technologies such as large-scale rapid screening, combinatorial chemistry and genetic engineering have accelerated the process of drug development. The research and development of anti-tumor drugs have been into a new era.

According to our (Global Info Research) latest study, the global Anti-tumor Drug market size was valued at USD million in 2022 and is forecast to a readjusted size of USD million by 2029 with a CAGR of % during review period. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.

In China, Anti-tumor Drug key players include AstraZeneca, Merck & Co., Roche, Celgene, Johnson & Johnson, etc.

United States is the largest market, followed by Japan, and Europe.

This report is a detailed and comprehensive analysis for global Anti-tumor Drug market. Both quantitative and qualitative analyses are presented by company, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2023, are provided.

Key Features:
Global Anti-tumor Drug market size and forecasts, in consumption value ($ Million), 2018-2029
Global Anti-tumor Drug market size and forecasts by region and country, in consumption value ($ Million), 2018-2029
Global Anti-tumor Drug market size and forecasts, by Type and by Application, in consumption value ($ Million), 2018-2029
Global Anti-tumor Drug market shares of main players, in revenue ($ Million), 2018-2023
The Primary Objectives in This Report Are:
To determine the size of the total market opportunity of global and key countries
To assess the growth potential for Anti-tumor Drug
To forecast future growth in each product and end-use market
To assess competitive factors affecting the marketplace
This report profiles key players in the global Anti-tumor Drug market based on the following parameters - company overview, production, value, price, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Roche, Novartis, Celgene, Bristol-Myers Squibb and Amgen, etc.

This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, COVID-19 and Russia-Ukraine War Influence.

Market segmentation
Anti-tumor Drug market is split by Type and by Application. For the period 2018-2029, the growth among segments provide accurate calculations and forecasts for consumption value by Type and by Application. This analysis can help you expand your business by targeting qualified niche markets.

Market segment by Type
    Cytotoxic Drugs
    Non-cytotoxic Drugs

Market segment by Application
    Alkylating Agents
    Anti-Metabolism Drugs
    Platinum Antineoplastic Agents
    Anthracycline Antitumor Drugs
    Microtubule Stabilizer
    Endocrine Therapy Drugs
    Immunotherapy Drugs
    Gene Therapy Drugs
    Targeted Antineoplastic Drugs

Market segment by players, this report covers
    Roche
    Novartis
    Celgene
    Bristol-Myers Squibb
    Amgen
    Johnson & Johnson
    Pfizer
    Takeda
    Eli Lilly
    AstraZeneca
    Astellas
    Merck & Co
    Sanofi
    Bayer
    Biogen Idec
    Eisai
    Teva
    Otsuka

Market segment by regions, regional analysis covers
    North America (United States, Canada, and Mexico)
    Europe (Germany, France, UK, Russia, Italy, and Rest of Europe)
    Asia-Pacific (China, Japan, South Korea, India, Southeast Asia, Australia and Rest of Asia-Pacific)
    South America (Brazil, Argentina and Rest of South America)
    Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of Middle East & Africa)

The content of the study subjects, includes a total of 13 chapters:
Chapter 1, to describe Anti-tumor Drug product scope, market overview, market estimation caveats and base year.
Chapter 2, to profile the top players of Anti-tumor Drug, with revenue, gross margin and global market share of Anti-tumor Drug from 2018 to 2023.
Chapter 3, the Anti-tumor Drug competitive situation, revenue and global market share of top players are analyzed emphatically by landscape contrast.
Chapter 4 and 5, to segment the market size by Type and application, with consumption value and growth rate by Type, application, from 2018 to 2029.
Chapter 6, 7, 8, 9, and 10, to break the market size data at the country level, with revenue and market share for key countries in the world, from 2018 to 2023.and Anti-tumor Drug market forecast, by regions, type and application, with consumption value, from 2024 to 2029.
Chapter 11, market dynamics, drivers, restraints, trends, Porters Five Forces analysis, and Influence of COVID-19 and Russia-Ukraine War
Chapter 12, the key raw materials and key suppliers, and industry chain of Anti-tumor Drug.
Chapter 13, to describe Anti-tumor Drug research findings and conclusion.

Table of Contents

1 Market Overview
    1.1 Product Overview and Scope of Anti-tumor Drug
    1.2 Market Estimation Caveats and Base Year
    1.3 Classification of Anti-tumor Drug by Type
        1.3.1 Overview: Global Anti-tumor Drug Market Size by Type: 2018 Versus 2022 Versus 2029
        1.3.2 Global Anti-tumor Drug Consumption Value Market Share by Type in 2022
        1.3.3 Cytotoxic Drugs
        1.3.4 Non-cytotoxic Drugs
    1.4 Global Anti-tumor Drug Market by Application
        1.4.1 Overview: Global Anti-tumor Drug Market Size by Application: 2018 Versus 2022 Versus 2029
        1.4.2 Alkylating Agents
        1.4.3 Anti-Metabolism Drugs
        1.4.4 Platinum Antineoplastic Agents
        1.4.5 Anthracycline Antitumor Drugs
        1.4.6 Microtubule Stabilizer
        1.4.7 Endocrine Therapy Drugs
        1.4.8 Immunotherapy Drugs
        1.4.9 Gene Therapy Drugs
        1.4.10 Targeted Antineoplastic Drugs
    1.5 Global Anti-tumor Drug Market Size & Forecast
    1.6 Global Anti-tumor Drug Market Size and Forecast by Region
        1.6.1 Global Anti-tumor Drug Market Size by Region: 2018 VS 2022 VS 2029
        1.6.2 Global Anti-tumor Drug Market Size by Region, (2018-2029)
        1.6.3 North America Anti-tumor Drug Market Size and Prospect (2018-2029)
        1.6.4 Europe Anti-tumor Drug Market Size and Prospect (2018-2029)
        1.6.5 Asia-Pacific Anti-tumor Drug Market Size and Prospect (2018-2029)
        1.6.6 South America Anti-tumor Drug Market Size and Prospect (2018-2029)
        1.6.7 Middle East and Africa Anti-tumor Drug Market Size and Prospect (2018-2029)

2 Company Profiles
    2.1 Roche
        2.1.1 Roche Details
        2.1.2 Roche Major Business
        2.1.3 Roche Anti-tumor Drug Product and Solutions
        2.1.4 Roche Anti-tumor Drug Revenue, Gross Margin and Market Share (2018-2023)
        2.1.5 Roche Recent Developments and Future Plans
    2.2 Novartis
        2.2.1 Novartis Details
        2.2.2 Novartis Major Business
        2.2.3 Novartis Anti-tumor Drug Product and Solutions
        2.2.4 Novartis Anti-tumor Drug Revenue, Gross Margin and Market Share (2018-2023)
        2.2.5 Novartis Recent Developments and Future Plans
    2.3 Celgene
        2.3.1 Celgene Details
        2.3.2 Celgene Major Business
        2.3.3 Celgene Anti-tumor Drug Product and Solutions
        2.3.4 Celgene Anti-tumor Drug Revenue, Gross Margin and Market Share (2018-2023)
        2.3.5 Celgene Recent Developments and Future Plans
    2.4 Bristol-Myers Squibb
        2.4.1 Bristol-Myers Squibb Details
        2.4.2 Bristol-Myers Squibb Major Business
        2.4.3 Bristol-Myers Squibb Anti-tumor Drug Product and Solutions
        2.4.4 Bristol-Myers Squibb Anti-tumor Drug Revenue, Gross Margin and Market Share (2018-2023)
        2.4.5 Bristol-Myers Squibb Recent Developments and Future Plans
    2.5 Amgen
        2.5.1 Amgen Details
        2.5.2 Amgen Major Business
        2.5.3 Amgen Anti-tumor Drug Product and Solutions
        2.5.4 Amgen Anti-tumor Drug Revenue, Gross Margin and Market Share (2018-2023)
        2.5.5 Amgen Recent Developments and Future Plans
    2.6 Johnson & Johnson
        2.6.1 Johnson & Johnson Details
        2.6.2 Johnson & Johnson Major Business
        2.6.3 Johnson & Johnson Anti-tumor Drug Product and Solutions
        2.6.4 Johnson & Johnson Anti-tumor Drug Revenue, Gross Margin and Market Share (2018-2023)
        2.6.5 Johnson & Johnson Recent Developments and Future Plans
    2.7 Pfizer
        2.7.1 Pfizer Details
        2.7.2 Pfizer Major Business
        2.7.3 Pfizer Anti-tumor Drug Product and Solutions
        2.7.4 Pfizer Anti-tumor Drug Revenue, Gross Margin and Market Share (2018-2023)
        2.7.5 Pfizer Recent Developments and Future Plans
    2.8 Takeda
        2.8.1 Takeda Details
        2.8.2 Takeda Major Business
        2.8.3 Takeda Anti-tumor Drug Product and Solutions
        2.8.4 Takeda Anti-tumor Drug Revenue, Gross Margin and Market Share (2018-2023)
        2.8.5 Takeda Recent Developments and Future Plans
    2.9 Eli Lilly
        2.9.1 Eli Lilly Details
        2.9.2 Eli Lilly Major Business
        2.9.3 Eli Lilly Anti-tumor Drug Product and Solutions
        2.9.4 Eli Lilly Anti-tumor Drug Revenue, Gross Margin and Market Share (2018-2023)
        2.9.5 Eli Lilly Recent Developments and Future Plans
    2.10 AstraZeneca
        2.10.1 AstraZeneca Details
        2.10.2 AstraZeneca Major Business
        2.10.3 AstraZeneca Anti-tumor Drug Product and Solutions
        2.10.4 AstraZeneca Anti-tumor Drug Revenue, Gross Margin and Market Share (2018-2023)
        2.10.5 AstraZeneca Recent Developments and Future Plans
    2.11 Astellas
        2.11.1 Astellas Details
        2.11.2 Astellas Major Business
        2.11.3 Astellas Anti-tumor Drug Product and Solutions
        2.11.4 Astellas Anti-tumor Drug Revenue, Gross Margin and Market Share (2018-2023)
        2.11.5 Astellas Recent Developments and Future Plans
    2.12 Merck & Co
        2.12.1 Merck & Co Details
        2.12.2 Merck & Co Major Business
        2.12.3 Merck & Co Anti-tumor Drug Product and Solutions
        2.12.4 Merck & Co Anti-tumor Drug Revenue, Gross Margin and Market Share (2018-2023)
        2.12.5 Merck & Co Recent Developments and Future Plans
    2.13 Sanofi
        2.13.1 Sanofi Details
        2.13.2 Sanofi Major Business
        2.13.3 Sanofi Anti-tumor Drug Product and Solutions
        2.13.4 Sanofi Anti-tumor Drug Revenue, Gross Margin and Market Share (2018-2023)
        2.13.5 Sanofi Recent Developments and Future Plans
    2.14 Bayer
        2.14.1 Bayer Details
        2.14.2 Bayer Major Business
        2.14.3 Bayer Anti-tumor Drug Product and Solutions
        2.14.4 Bayer Anti-tumor Drug Revenue, Gross Margin and Market Share (2018-2023)
        2.14.5 Bayer Recent Developments and Future Plans
    2.15 Biogen Idec
        2.15.1 Biogen Idec Details
        2.15.2 Biogen Idec Major Business
        2.15.3 Biogen Idec Anti-tumor Drug Product and Solutions
        2.15.4 Biogen Idec Anti-tumor Drug Revenue, Gross Margin and Market Share (2018-2023)
        2.15.5 Biogen Idec Recent Developments and Future Plans
    2.16 Eisai
        2.16.1 Eisai Details
        2.16.2 Eisai Major Business
        2.16.3 Eisai Anti-tumor Drug Product and Solutions
        2.16.4 Eisai Anti-tumor Drug Revenue, Gross Margin and Market Share (2018-2023)
        2.16.5 Eisai Recent Developments and Future Plans
    2.17 Teva
        2.17.1 Teva Details
        2.17.2 Teva Major Business
        2.17.3 Teva Anti-tumor Drug Product and Solutions
        2.17.4 Teva Anti-tumor Drug Revenue, Gross Margin and Market Share (2018-2023)
        2.17.5 Teva Recent Developments and Future Plans
    2.18 Otsuka
        2.18.1 Otsuka Details
        2.18.2 Otsuka Major Business
        2.18.3 Otsuka Anti-tumor Drug Product and Solutions
        2.18.4 Otsuka Anti-tumor Drug Revenue, Gross Margin and Market Share (2018-2023)
        2.18.5 Otsuka Recent Developments and Future Plans

3 Market Competition, by Players
    3.1 Global Anti-tumor Drug Revenue and Share by Players (2018-2023)
    3.2 Market Share Analysis (2022)
        3.2.1 Market Share of Anti-tumor Drug by Company Revenue
        3.2.2 Top 3 Anti-tumor Drug Players Market Share in 2022
        3.2.3 Top 6 Anti-tumor Drug Players Market Share in 2022
    3.3 Anti-tumor Drug Market: Overall Company Footprint Analysis
        3.3.1 Anti-tumor Drug Market: Region Footprint
        3.3.2 Anti-tumor Drug Market: Company Product Type Footprint
        3.3.3 Anti-tumor Drug Market: Company Product Application Footprint
    3.4 New Market Entrants and Barriers to Market Entry
    3.5 Mergers, Acquisition, Agreements, and Collaborations

4 Market Size Segment by Type
    4.1 Global Anti-tumor Drug Consumption Value and Market Share by Type (2018-2023)
    4.2 Global Anti-tumor Drug Market Forecast by Type (2024-2029)

5 Market Size Segment by Application
    5.1 Global Anti-tumor Drug Consumption Value Market Share by Application (2018-2023)
    5.2 Global Anti-tumor Drug Market Forecast by Application (2024-2029)

6 North America
    6.1 North America Anti-tumor Drug Consumption Value by Type (2018-2029)
    6.2 North America Anti-tumor Drug Consumption Value by Application (2018-2029)
    6.3 North America Anti-tumor Drug Market Size by Country
        6.3.1 North America Anti-tumor Drug Consumption Value by Country (2018-2029)
        6.3.2 United States Anti-tumor Drug Market Size and Forecast (2018-2029)
        6.3.3 Canada Anti-tumor Drug Market Size and Forecast (2018-2029)
        6.3.4 Mexico Anti-tumor Drug Market Size and Forecast (2018-2029)

7 Europe
    7.1 Europe Anti-tumor Drug Consumption Value by Type (2018-2029)
    7.2 Europe Anti-tumor Drug Consumption Value by Application (2018-2029)
    7.3 Europe Anti-tumor Drug Market Size by Country
        7.3.1 Europe Anti-tumor Drug Consumption Value by Country (2018-2029)
        7.3.2 Germany Anti-tumor Drug Market Size and Forecast (2018-2029)
        7.3.3 France Anti-tumor Drug Market Size and Forecast (2018-2029)
        7.3.4 United Kingdom Anti-tumor Drug Market Size and Forecast (2018-2029)
        7.3.5 Russia Anti-tumor Drug Market Size and Forecast (2018-2029)
        7.3.6 Italy Anti-tumor Drug Market Size and Forecast (2018-2029)

8 Asia-Pacific
    8.1 Asia-Pacific Anti-tumor Drug Consumption Value by Type (2018-2029)
    8.2 Asia-Pacific Anti-tumor Drug Consumption Value by Application (2018-2029)
    8.3 Asia-Pacific Anti-tumor Drug Market Size by Region
        8.3.1 Asia-Pacific Anti-tumor Drug Consumption Value by Region (2018-2029)
        8.3.2 China Anti-tumor Drug Market Size and Forecast (2018-2029)
        8.3.3 Japan Anti-tumor Drug Market Size and Forecast (2018-2029)
        8.3.4 South Korea Anti-tumor Drug Market Size and Forecast (2018-2029)
        8.3.5 India Anti-tumor Drug Market Size and Forecast (2018-2029)
        8.3.6 Southeast Asia Anti-tumor Drug Market Size and Forecast (2018-2029)
        8.3.7 Australia Anti-tumor Drug Market Size and Forecast (2018-2029)

9 South America
    9.1 South America Anti-tumor Drug Consumption Value by Type (2018-2029)
    9.2 South America Anti-tumor Drug Consumption Value by Application (2018-2029)
    9.3 South America Anti-tumor Drug Market Size by Country
        9.3.1 South America Anti-tumor Drug Consumption Value by Country (2018-2029)
        9.3.2 Brazil Anti-tumor Drug Market Size and Forecast (2018-2029)
        9.3.3 Argentina Anti-tumor Drug Market Size and Forecast (2018-2029)

10 Middle East & Africa
    10.1 Middle East & Africa Anti-tumor Drug Consumption Value by Type (2018-2029)
    10.2 Middle East & Africa Anti-tumor Drug Consumption Value by Application (2018-2029)
    10.3 Middle East & Africa Anti-tumor Drug Market Size by Country
        10.3.1 Middle East & Africa Anti-tumor Drug Consumption Value by Country (2018-2029)
        10.3.2 Turkey Anti-tumor Drug Market Size and Forecast (2018-2029)
        10.3.3 Saudi Arabia Anti-tumor Drug Market Size and Forecast (2018-2029)
        10.3.4 UAE Anti-tumor Drug Market Size and Forecast (2018-2029)

11 Market Dynamics
    11.1 Anti-tumor Drug Market Drivers
    11.2 Anti-tumor Drug Market Restraints
    11.3 Anti-tumor Drug Trends Analysis
    11.4 Porters Five Forces Analysis
        11.4.1 Threat of New Entrants
        11.4.2 Bargaining Power of Suppliers
        11.4.3 Bargaining Power of Buyers
        11.4.4 Threat of Substitutes
        11.4.5 Competitive Rivalry
    11.5 Influence of COVID-19 and Russia-Ukraine War
        11.5.1 Influence of COVID-19
        11.5.2 Influence of Russia-Ukraine War

12 Industry Chain Analysis
    12.1 Anti-tumor Drug Industry Chain
    12.2 Anti-tumor Drug Upstream Analysis
    12.3 Anti-tumor Drug Midstream Analysis
    12.4 Anti-tumor Drug Downstream Analysis

13 Research Findings and Conclusion

14 Appendix
    14.1 Methodology
    14.2 Research Process and Data Source
    14.3 Disclaimer

Table of Figures

List of Tables
    Table 1. Global Anti-tumor Drug Consumption Value by Type, (USD Million), 2018 & 2022 & 2029
    Table 2. Global Anti-tumor Drug Consumption Value by Application, (USD Million), 2018 & 2022 & 2029
    Table 3. Global Anti-tumor Drug Consumption Value by Region (2018-2023) & (USD Million)
    Table 4. Global Anti-tumor Drug Consumption Value by Region (2024-2029) & (USD Million)
    Table 5. Roche Company Information, Head Office, and Major Competitors
    Table 6. Roche Major Business
    Table 7. Roche Anti-tumor Drug Product and Solutions
    Table 8. Roche Anti-tumor Drug Revenue (USD Million), Gross Margin and Market Share (2018-2023)
    Table 9. Roche Recent Developments and Future Plans
    Table 10. Novartis Company Information, Head Office, and Major Competitors
    Table 11. Novartis Major Business
    Table 12. Novartis Anti-tumor Drug Product and Solutions
    Table 13. Novartis Anti-tumor Drug Revenue (USD Million), Gross Margin and Market Share (2018-2023)
    Table 14. Novartis Recent Developments and Future Plans
    Table 15. Celgene Company Information, Head Office, and Major Competitors
    Table 16. Celgene Major Business
    Table 17. Celgene Anti-tumor Drug Product and Solutions
    Table 18. Celgene Anti-tumor Drug Revenue (USD Million), Gross Margin and Market Share (2018-2023)
    Table 19. Celgene Recent Developments and Future Plans
    Table 20. Bristol-Myers Squibb Company Information, Head Office, and Major Competitors
    Table 21. Bristol-Myers Squibb Major Business
    Table 22. Bristol-Myers Squibb Anti-tumor Drug Product and Solutions
    Table 23. Bristol-Myers Squibb Anti-tumor Drug Revenue (USD Million), Gross Margin and Market Share (2018-2023)
    Table 24. Bristol-Myers Squibb Recent Developments and Future Plans
    Table 25. Amgen Company Information, Head Office, and Major Competitors
    Table 26. Amgen Major Business
    Table 27. Amgen Anti-tumor Drug Product and Solutions
    Table 28. Amgen Anti-tumor Drug Revenue (USD Million), Gross Margin and Market Share (2018-2023)
    Table 29. Amgen Recent Developments and Future Plans
    Table 30. Johnson & Johnson Company Information, Head Office, and Major Competitors
    Table 31. Johnson & Johnson Major Business
    Table 32. Johnson & Johnson Anti-tumor Drug Product and Solutions
    Table 33. Johnson & Johnson Anti-tumor Drug Revenue (USD Million), Gross Margin and Market Share (2018-2023)
    Table 34. Johnson & Johnson Recent Developments and Future Plans
    Table 35. Pfizer Company Information, Head Office, and Major Competitors
    Table 36. Pfizer Major Business
    Table 37. Pfizer Anti-tumor Drug Product and Solutions
    Table 38. Pfizer Anti-tumor Drug Revenue (USD Million), Gross Margin and Market Share (2018-2023)
    Table 39. Pfizer Recent Developments and Future Plans
    Table 40. Takeda Company Information, Head Office, and Major Competitors
    Table 41. Takeda Major Business
    Table 42. Takeda Anti-tumor Drug Product and Solutions
    Table 43. Takeda Anti-tumor Drug Revenue (USD Million), Gross Margin and Market Share (2018-2023)
    Table 44. Takeda Recent Developments and Future Plans
    Table 45. Eli Lilly Company Information, Head Office, and Major Competitors
    Table 46. Eli Lilly Major Business
    Table 47. Eli Lilly Anti-tumor Drug Product and Solutions
    Table 48. Eli Lilly Anti-tumor Drug Revenue (USD Million), Gross Margin and Market Share (2018-2023)
    Table 49. Eli Lilly Recent Developments and Future Plans
    Table 50. AstraZeneca Company Information, Head Office, and Major Competitors
    Table 51. AstraZeneca Major Business
    Table 52. AstraZeneca Anti-tumor Drug Product and Solutions
    Table 53. AstraZeneca Anti-tumor Drug Revenue (USD Million), Gross Margin and Market Share (2018-2023)
    Table 54. AstraZeneca Recent Developments and Future Plans
    Table 55. Astellas Company Information, Head Office, and Major Competitors
    Table 56. Astellas Major Business
    Table 57. Astellas Anti-tumor Drug Product and Solutions
    Table 58. Astellas Anti-tumor Drug Revenue (USD Million), Gross Margin and Market Share (2018-2023)
    Table 59. Astellas Recent Developments and Future Plans
    Table 60. Merck & Co Company Information, Head Office, and Major Competitors
    Table 61. Merck & Co Major Business
    Table 62. Merck & Co Anti-tumor Drug Product and Solutions
    Table 63. Merck & Co Anti-tumor Drug Revenue (USD Million), Gross Margin and Market Share (2018-2023)
    Table 64. Merck & Co Recent Developments and Future Plans
    Table 65. Sanofi Company Information, Head Office, and Major Competitors
    Table 66. Sanofi Major Business
    Table 67. Sanofi Anti-tumor Drug Product and Solutions
    Table 68. Sanofi Anti-tumor Drug Revenue (USD Million), Gross Margin and Market Share (2018-2023)
    Table 69. Sanofi Recent Developments and Future Plans
    Table 70. Bayer Company Information, Head Office, and Major Competitors
    Table 71. Bayer Major Business
    Table 72. Bayer Anti-tumor Drug Product and Solutions
    Table 73. Bayer Anti-tumor Drug Revenue (USD Million), Gross Margin and Market Share (2018-2023)
    Table 74. Bayer Recent Developments and Future Plans
    Table 75. Biogen Idec Company Information, Head Office, and Major Competitors
    Table 76. Biogen Idec Major Business
    Table 77. Biogen Idec Anti-tumor Drug Product and Solutions
    Table 78. Biogen Idec Anti-tumor Drug Revenue (USD Million), Gross Margin and Market Share (2018-2023)
    Table 79. Biogen Idec Recent Developments and Future Plans
    Table 80. Eisai Company Information, Head Office, and Major Competitors
    Table 81. Eisai Major Business
    Table 82. Eisai Anti-tumor Drug Product and Solutions
    Table 83. Eisai Anti-tumor Drug Revenue (USD Million), Gross Margin and Market Share (2018-2023)
    Table 84. Eisai Recent Developments and Future Plans
    Table 85. Teva Company Information, Head Office, and Major Competitors
    Table 86. Teva Major Business
    Table 87. Teva Anti-tumor Drug Product and Solutions
    Table 88. Teva Anti-tumor Drug Revenue (USD Million), Gross Margin and Market Share (2018-2023)
    Table 89. Teva Recent Developments and Future Plans
    Table 90. Otsuka Company Information, Head Office, and Major Competitors
    Table 91. Otsuka Major Business
    Table 92. Otsuka Anti-tumor Drug Product and Solutions
    Table 93. Otsuka Anti-tumor Drug Revenue (USD Million), Gross Margin and Market Share (2018-2023)
    Table 94. Otsuka Recent Developments and Future Plans
    Table 95. Global Anti-tumor Drug Revenue (USD Million) by Players (2018-2023)
    Table 96. Global Anti-tumor Drug Revenue Share by Players (2018-2023)
    Table 97. Breakdown of Anti-tumor Drug by Company Type (Tier 1, Tier 2, and Tier 3)
    Table 98. Market Position of Players in Anti-tumor Drug, (Tier 1, Tier 2, and Tier 3), Based on Revenue in 2022
    Table 99. Head Office of Key Anti-tumor Drug Players
    Table 100. Anti-tumor Drug Market: Company Product Type Footprint
    Table 101. Anti-tumor Drug Market: Company Product Application Footprint
    Table 102. Anti-tumor Drug New Market Entrants and Barriers to Market Entry
    Table 103. Anti-tumor Drug Mergers, Acquisition, Agreements, and Collaborations
    Table 104. Global Anti-tumor Drug Consumption Value (USD Million) by Type (2018-2023)
    Table 105. Global Anti-tumor Drug Consumption Value Share by Type (2018-2023)
    Table 106. Global Anti-tumor Drug Consumption Value Forecast by Type (2024-2029)
    Table 107. Global Anti-tumor Drug Consumption Value by Application (2018-2023)
    Table 108. Global Anti-tumor Drug Consumption Value Forecast by Application (2024-2029)
    Table 109. North America Anti-tumor Drug Consumption Value by Type (2018-2023) & (USD Million)
    Table 110. North America Anti-tumor Drug Consumption Value by Type (2024-2029) & (USD Million)
    Table 111. North America Anti-tumor Drug Consumption Value by Application (2018-2023) & (USD Million)
    Table 112. North America Anti-tumor Drug Consumption Value by Application (2024-2029) & (USD Million)
    Table 113. North America Anti-tumor Drug Consumption Value by Country (2018-2023) & (USD Million)
    Table 114. North America Anti-tumor Drug Consumption Value by Country (2024-2029) & (USD Million)
    Table 115. Europe Anti-tumor Drug Consumption Value by Type (2018-2023) & (USD Million)
    Table 116. Europe Anti-tumor Drug Consumption Value by Type (2024-2029) & (USD Million)
    Table 117. Europe Anti-tumor Drug Consumption Value by Application (2018-2023) & (USD Million)
    Table 118. Europe Anti-tumor Drug Consumption Value by Application (2024-2029) & (USD Million)
    Table 119. Europe Anti-tumor Drug Consumption Value by Country (2018-2023) & (USD Million)
    Table 120. Europe Anti-tumor Drug Consumption Value by Country (2024-2029) & (USD Million)
    Table 121. Asia-Pacific Anti-tumor Drug Consumption Value by Type (2018-2023) & (USD Million)
    Table 122. Asia-Pacific Anti-tumor Drug Consumption Value by Type (2024-2029) & (USD Million)
    Table 123. Asia-Pacific Anti-tumor Drug Consumption Value by Application (2018-2023) & (USD Million)
    Table 124. Asia-Pacific Anti-tumor Drug Consumption Value by Application (2024-2029) & (USD Million)
    Table 125. Asia-Pacific Anti-tumor Drug Consumption Value by Region (2018-2023) & (USD Million)
    Table 126. Asia-Pacific Anti-tumor Drug Consumption Value by Region (2024-2029) & (USD Million)
    Table 127. South America Anti-tumor Drug Consumption Value by Type (2018-2023) & (USD Million)
    Table 128. South America Anti-tumor Drug Consumption Value by Type (2024-2029) & (USD Million)
    Table 129. South America Anti-tumor Drug Consumption Value by Application (2018-2023) & (USD Million)
    Table 130. South America Anti-tumor Drug Consumption Value by Application (2024-2029) & (USD Million)
    Table 131. South America Anti-tumor Drug Consumption Value by Country (2018-2023) & (USD Million)
    Table 132. South America Anti-tumor Drug Consumption Value by Country (2024-2029) & (USD Million)
    Table 133. Middle East & Africa Anti-tumor Drug Consumption Value by Type (2018-2023) & (USD Million)
    Table 134. Middle East & Africa Anti-tumor Drug Consumption Value by Type (2024-2029) & (USD Million)
    Table 135. Middle East & Africa Anti-tumor Drug Consumption Value by Application (2018-2023) & (USD Million)
    Table 136. Middle East & Africa Anti-tumor Drug Consumption Value by Application (2024-2029) & (USD Million)
    Table 137. Middle East & Africa Anti-tumor Drug Consumption Value by Country (2018-2023) & (USD Million)
    Table 138. Middle East & Africa Anti-tumor Drug Consumption Value by Country (2024-2029) & (USD Million)
    Table 139. Anti-tumor Drug Raw Material
    Table 140. Key Suppliers of Anti-tumor Drug Raw Materials
List of Figures
    Figure 1. Anti-tumor Drug Picture
    Figure 2. Global Anti-tumor Drug Consumption Value by Type, (USD Million), 2018 & 2022 & 2029
    Figure 3. Global Anti-tumor Drug Consumption Value Market Share by Type in 2022
    Figure 4. Cytotoxic Drugs
    Figure 5. Non-cytotoxic Drugs
    Figure 6. Global Anti-tumor Drug Consumption Value by Type, (USD Million), 2018 & 2022 & 2029
    Figure 7. Anti-tumor Drug Consumption Value Market Share by Application in 2022
    Figure 8. Alkylating Agents Picture
    Figure 9. Anti-Metabolism Drugs Picture
    Figure 10. Platinum Antineoplastic Agents Picture
    Figure 11. Anthracycline Antitumor Drugs Picture
    Figure 12. Microtubule Stabilizer Picture
    Figure 13. Endocrine Therapy Drugs Picture
    Figure 14. Immunotherapy Drugs Picture
    Figure 15. Gene Therapy Drugs Picture
    Figure 16. Targeted Antineoplastic Drugs Picture
    Figure 17. Global Anti-tumor Drug Consumption Value, (USD Million): 2018 & 2022 & 2029
    Figure 18. Global Anti-tumor Drug Consumption Value and Forecast (2018-2029) & (USD Million)
    Figure 19. Global Market Anti-tumor Drug Consumption Value (USD Million) Comparison by Region (2018 & 2022 & 2029)
    Figure 20. Global Anti-tumor Drug Consumption Value Market Share by Region (2018-2029)
    Figure 21. Global Anti-tumor Drug Consumption Value Market Share by Region in 2022
    Figure 22. North America Anti-tumor Drug Consumption Value (2018-2029) & (USD Million)
    Figure 23. Europe Anti-tumor Drug Consumption Value (2018-2029) & (USD Million)
    Figure 24. Asia-Pacific Anti-tumor Drug Consumption Value (2018-2029) & (USD Million)
    Figure 25. South America Anti-tumor Drug Consumption Value (2018-2029) & (USD Million)
    Figure 26. Middle East and Africa Anti-tumor Drug Consumption Value (2018-2029) & (USD Million)
    Figure 27. Global Anti-tumor Drug Revenue Share by Players in 2022
    Figure 28. Anti-tumor Drug Market Share by Company Type (Tier 1, Tier 2 and Tier 3) in 2022
    Figure 29. Global Top 3 Players Anti-tumor Drug Market Share in 2022
    Figure 30. Global Top 6 Players Anti-tumor Drug Market Share in 2022
    Figure 31. Global Anti-tumor Drug Consumption Value Share by Type (2018-2023)
    Figure 32. Global Anti-tumor Drug Market Share Forecast by Type (2024-2029)
    Figure 33. Global Anti-tumor Drug Consumption Value Share by Application (2018-2023)
    Figure 34. Global Anti-tumor Drug Market Share Forecast by Application (2024-2029)
    Figure 35. North America Anti-tumor Drug Consumption Value Market Share by Type (2018-2029)
    Figure 36. North America Anti-tumor Drug Consumption Value Market Share by Application (2018-2029)
    Figure 37. North America Anti-tumor Drug Consumption Value Market Share by Country (2018-2029)
    Figure 38. United States Anti-tumor Drug Consumption Value (2018-2029) & (USD Million)
    Figure 39. Canada Anti-tumor Drug Consumption Value (2018-2029) & (USD Million)
    Figure 40. Mexico Anti-tumor Drug Consumption Value (2018-2029) & (USD Million)
    Figure 41. Europe Anti-tumor Drug Consumption Value Market Share by Type (2018-2029)
    Figure 42. Europe Anti-tumor Drug Consumption Value Market Share by Application (2018-2029)
    Figure 43. Europe Anti-tumor Drug Consumption Value Market Share by Country (2018-2029)
    Figure 44. Germany Anti-tumor Drug Consumption Value (2018-2029) & (USD Million)
    Figure 45. France Anti-tumor Drug Consumption Value (2018-2029) & (USD Million)
    Figure 46. United Kingdom Anti-tumor Drug Consumption Value (2018-2029) & (USD Million)
    Figure 47. Russia Anti-tumor Drug Consumption Value (2018-2029) & (USD Million)
    Figure 48. Italy Anti-tumor Drug Consumption Value (2018-2029) & (USD Million)
    Figure 49. Asia-Pacific Anti-tumor Drug Consumption Value Market Share by Type (2018-2029)
    Figure 50. Asia-Pacific Anti-tumor Drug Consumption Value Market Share by Application (2018-2029)
    Figure 51. Asia-Pacific Anti-tumor Drug Consumption Value Market Share by Region (2018-2029)
    Figure 52. China Anti-tumor Drug Consumption Value (2018-2029) & (USD Million)
    Figure 53. Japan Anti-tumor Drug Consumption Value (2018-2029) & (USD Million)
    Figure 54. South Korea Anti-tumor Drug Consumption Value (2018-2029) & (USD Million)
    Figure 55. India Anti-tumor Drug Consumption Value (2018-2029) & (USD Million)
    Figure 56. Southeast Asia Anti-tumor Drug Consumption Value (2018-2029) & (USD Million)
    Figure 57. Australia Anti-tumor Drug Consumption Value (2018-2029) & (USD Million)
    Figure 58. South America Anti-tumor Drug Consumption Value Market Share by Type (2018-2029)
    Figure 59. South America Anti-tumor Drug Consumption Value Market Share by Application (2018-2029)
    Figure 60. South America Anti-tumor Drug Consumption Value Market Share by Country (2018-2029)
    Figure 61. Brazil Anti-tumor Drug Consumption Value (2018-2029) & (USD Million)
    Figure 62. Argentina Anti-tumor Drug Consumption Value (2018-2029) & (USD Million)
    Figure 63. Middle East and Africa Anti-tumor Drug Consumption Value Market Share by Type (2018-2029)
    Figure 64. Middle East and Africa Anti-tumor Drug Consumption Value Market Share by Application (2018-2029)
    Figure 65. Middle East and Africa Anti-tumor Drug Consumption Value Market Share by Country (2018-2029)
    Figure 66. Turkey Anti-tumor Drug Consumption Value (2018-2029) & (USD Million)
    Figure 67. Saudi Arabia Anti-tumor Drug Consumption Value (2018-2029) & (USD Million)
    Figure 68. UAE Anti-tumor Drug Consumption Value (2018-2029) & (USD Million)
    Figure 69. Anti-tumor Drug Market Drivers
    Figure 70. Anti-tumor Drug Market Restraints
    Figure 71. Anti-tumor Drug Market Trends
    Figure 72. Porters Five Forces Analysis
    Figure 73. Manufacturing Cost Structure Analysis of Anti-tumor Drug in 2022
    Figure 74. Manufacturing Process Analysis of Anti-tumor Drug
    Figure 75. Anti-tumor Drug Industrial Chain
    Figure 76. Methodology
    Figure 77. Research Process and Data Source